New cellular and molecular targets for the treatment of portal hypertension.

New cellular and molecular targets for the treatment of portal hypertension.

Item
http://www.wikidata.org/entity/Q38383418
Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stressReversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1.How to Face Chronic Liver Disease: The Sinusoidal Perspective.PAI-1 4G-4G and MTHFR 677TT in non-hepatitis C virus/hepatitis B virus-related liver cirrhosis.Clinical value of liver and spleen shear wave velocity in predicting the prognosis of patients with portal hypertension.Lineage tracing reveals conversion of liver sinusoidal endothelial cells into hepatocytes.Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells in vivo and in vitro by activating AMP-activated protein kinase.Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells in vivo and in vitro by activating AMP-activated protein kinase.
P2860

New cellular and molecular targets for the treatment of portal hypertension.

Item
http://www.wikidata.org/entity/Q38383418
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
New cellular and molecular targets for the treatment of portal hypertension.
@en
type
label
New cellular and molecular targets for the treatment of portal hypertension.
@en
prefLabel
New cellular and molecular targets for the treatment of portal hypertension.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P6179
P698
P356
P1433
P1476
New cellular and molecular targets for the treatment of portal hypertension.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P6179
P698